Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety of Anti-TNF Antibodies, Including Biosimilars, in Treatment of Inflammatory Bowel Disease: Multicentre Cohort Observational Study (SATIMOS)

NCT02066272 is registered in ClinicalTrials.gov with Maria Sklodowska-Curie National Research Institute of Oncology as lead sponsor.

NCT NCT02066272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02066272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety of Anti-TNF Antibodies, Including Biosimilars, in Treatment of Inflammatory Bowel Disease: Multicentre Cohort Observational Study (SATIMOS)
Lead sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Phase
Observational
Overall status
Unknown status
Start date
January 31, 2014
Completion date
December 31, 2016
Enrollment
400 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease, indeterminate colitis, inflammatory bowel disease, ulcerative colitis